Latest Articles

Publication Date
Meta-analysis of the effect of goserelin acetate implant on improving hormone levels in patients with endometriosis.

Endometriosis is a hormone-related gynecological disease and characterized by the invasion of endometrial cells outside the uterine cavity.

Published: March 1, 2026, midnight
ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon - TipRanks

ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon TipRanks

Published: Feb. 27, 2026, 7:47 p.m.
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - MarketBeat

Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer MarketBeat

Published: Feb. 27, 2026, 4:50 p.m.
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - Yahoo Finance

Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer Yahoo Finance

Published: Feb. 27, 2026, 4:47 p.m.
ACRV: ACR-368 delivers strong efficacy and safety in serous endometrial cancer, advancing toward approval - TradingView

ACRV: ACR-368 delivers strong efficacy and safety in serous endometrial cancer, advancing toward approval TradingView

Published: Feb. 27, 2026, 3:34 p.m.
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data - TipRanks

Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data TipRanks

Published: Feb. 27, 2026, 3:24 p.m.
ACRV: ACR-368 shows high efficacy and safety in serous endometrial cancer, supporting global expansion - TradingView

ACRV: ACR-368 shows high efficacy and safety in serous endometrial cancer, supporting global expansion TradingView

Published: Feb. 27, 2026, 2:50 p.m.
Acrivon (NASDAQ: ACRV) shows ACR-368 activity in endometrial cancer - Stock Titan

Acrivon (NASDAQ: ACRV) shows ACR-368 activity in endometrial cancer Stock Titan

Published: Feb. 27, 2026, 2 p.m.
Establishment of a xenograft model of endometriosis-associated fibrosis using human immortalized endometrial stromal cells overexpressing HOXC8.

Endometriosis is a disease characterized by fibrosis and adhesions. There are still no treatment methods targeting these conditions. One reason for this is the lack of useful animal models to …

Published: Feb. 27, 2026, midnight
The inhibition of deep peritoneal endometriosis by Andrographolide through macrophage M1 activity in an endometriosis mice model.

This study aims to demonstrate that Andrographolide, an herbal immunostimulant, can influence M1 macrophages to inhibit inflammation, including the growth of endometriosis caused by inflammation. This study evaluates the effects …

Published: Feb. 27, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!